Evidence map›Paper›PMID 32197580›Full record

ArticleBMC bioinformatics2020

Standard machine learning approaches outperform deep representation learning on phenotype prediction from transcriptomics data.

Aaron M Smith, Jonathan R Walsh, John Long, Craig B Davis, Peter Henstock, Martin R Hodge, Mateusz Maciejewski, Xinmeng Jasmine Mu, Stephen Ra, Shanrong Zhao and 2 more

Abstract read
In one paragraph

Article in BMC bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aaron M SmithUnlearn.AI, Inc., San Francisco, CA, USA. drams@unlearn.ai.ORCID http://orcid.org/0000-0002-5998-8637
Jonathan R WalshUnlearn.AI, Inc., San Francisco, CA, USA.
John LongComputational Sciences, Worldwide Research & Development, Pfizer Inc., Cambridge, MA, USA.
Craig B DavisOncology Global Product Development, Pfizer Inc., San Diego, CA, USA.
Peter HenstockBusiness Technology, Pfizer Inc., Cambridge, MA, USA.
Martin R HodgeInflammation and Immunology, Worldwide Research & Development, Pfizer Inc., Cambridge, MA, USA.
Mateusz MaciejewskiInflammation and Immunology, Worldwide Research & Development, Pfizer Inc., Cambridge, MA, USA.
Xinmeng Jasmine MuOncology Research & Development, Worldwide Research & Development, Pfizer Inc., San Diego, CA, USA.
Stephen RaComputational Sciences, Worldwide Research & Development, Pfizer Inc., Cambridge, MA, USA.
Shanrong ZhaoComputational Sciences, Worldwide Research & Development, Pfizer Inc., Cambridge, MA, USA.
Daniel ZiemekInflammation and Immunology, Worldwide Research & Development, Pfizer Pharma GmbH., Berlin, Germany.
Charles K FisherUnlearn.AI, Inc., San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ability to confidently predict health outcomes from gene expression would catalyze a revolution in molecular diagnostics. Yet, the goal of developing actionable, robust, and reproducible predictive signatures of phenotypes such as clinical outcome has not been attained in almost any disease area. Here, we report a comprehensive analysis spanning prediction tasks from ulcerative colitis, atopic dermatitis, diabetes, to many cancer subtypes for a total of 24 binary and multiclass prediction problems and 26 survival analysis tasks. We systematically investigate the influence of gene subsets, normalization methods and prediction algorithms. Crucially, we also explore the novel use of deep representation learning methods on large transcriptomics compendia, such as GTEx and TCGA, to boost the performance of state-of-the-art methods. The resources and findings in this work should serve as both an up-to-date reference on attainable performance, and as a benchmarking resource for further research.

resultsApproaches that combine large numbers of genes outperformed single gene methods consistently and with a significant margin, but neither unsupervised nor semi-supervised representation learning techniques yielded consistent improvements in out-of-sample performance across datasets. Our findings suggest that using l

conclusionsTranscriptomics-based phenotype prediction benefits from proper normalization techniques and state-of-the-art regularized regression approaches. In our view, breakthrough performance is likely contingent on factors which are independent of normalization and general modeling techniques; these factors might include reduction of systematic errors in sequencing data, incorporation of other data types such as single-cell sequencing and proteomics, and improved use of prior knowledge.

Indexed as

Deep LearningGene Expression ProfilingMachine LearningPhenotypeDiseaseHumansSupervised Machine LearningDeep learningMachine learningMolecular diagnosticsNormalization methodsPhenotype predictionRepresentation learningRNA-seqTranscriptomics

Identifiers

PMID32197580
PMCPMC7085143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.